CS251545B1 - Therapeutic preparation for inflammatory and painful diseases - Google Patents

Abstract

A medicinal preparation against inflammatory and painful diseases, the essence of which is that it contains substances in the following weight ratio: Benzocyanates 8 to 12 weight parts Ketophenylbutazone 8 to 12 weight parts Pharmacologically suitable ointment base 41 to 74 weight parts and optionally also ether in the amount of 10 to 15 weight parts. The preparation is used in the form of an ointment and is suitable for the following diseases. Acute and chronic arthritis, rheumatoid arthritis, tendinitis and tendovaginitis, bursitis, phlebitis, distortions, arthralgia of various etiologies, incipient phlegmon, lymphadenitis and lymphangiitis, myositis, contusions, neuralgia, all inflammatory and painful syndromes as part of complex therapy.

Description

251545

BACKGROUND OF THE INVENTION The present invention relates to a medicament for treating inflammatory and painful diseases, such as rheumatic pain in the joints, painful tissue, contusions of the tissues, posterior muscles, inflammation of the veins, inflammation of the tendon, incipient inflammation of the skin, and skin, hunting, acute and chronic forms of rheumatic complaints, including the loss of tension and painful muscles and bruising and thickening. In the present time, there are preparations, and there is a Reparil-Gel, which is less effective in inflammatory processes of joints and veins, contusions, tendons of the tendon apparatus, recessive joints of the joints [Arztl. Prax.22, 970, 2,809, 4,863 (1970)]. Mobilisin ung., Whose onset of action is less severe, is less effective in venous and tendon inflammation, and must not be allowed to come into contact with mucous membranes and open wounds, also with an eczemaous goat. CeskoslOv. farm. 26, 1977, No. 3, Mobilat et al., Is poorly effective in inflammation of the veins, painful joints and joints, and must not come into contact with the mucous membranes and open arms, the eczematous goat. Ceskosl. 24, 1975, No. 9. Ketazone 1/0% ung., which may be effective in the treatment of bladder joints, joints, sprains, and muscular contusions, and should not be used in patients with pre-infliction on pyrazolidine antif logists jrady. Pharmacotherapeutic Reports Spofa288, 1975.

These preparations are disadvantageous in that the effect of action is over a long period of time, induces! allergic reactions in hypersensitive l’huds, only to a narrow spectrum of diseases, require the wearing of a dressing material, they must not come into contact with mucous membranes, formed wounds and eczematous goats, require medical prescription and post-use supervision.

The above mentioned drawbacks are solved by the invention, the substance of which is that it contains substances in this proportion by weight:

Benzoacetates 8-12 wt. parts

Ketophenylbutazones 8-12 wt. parts of a pharmacologically acceptable carrier 74 to 41 wt. parts

An example is zl-o-z:

Methylp-araben 200 mg

Propylparaben 50 mg

Paraffinum liquidum 8 g

Parraffinum durum 12 g

Alcbholum stearyli-cum 2 g

Slovatso-lum 243-0 2 g

Pr-opyleniglyic-olum rain. 5 g

Carbopolum 940 500 mg

600 mg triethanolamine

Aqua demineralisata ster. 69.65 g (= 100gramoiv ointment base) This type of ointment base is Ambider-man.

Aether 10 to 15 wt. The advantage of this preparation is that it acts as a rabbit for a period of time, does not require the wearing of a dressing material, the use is indicatively versatile, does not require medical predisposition, and thus can be used in the treatment of rabbits. without medical supervision. According to current experience, it does not cause adverse effects.

Clinics can be used in subsequent illnesses:

Acute and chronic arthritis, rheumatoid arthritis, teeddinitis and tendovaginitis, bursitis, skullitis, distortion, arthralgia of different ethology, incipient: phlegmones, lymphadenitis and ly-mphagitis, myositis, contusion, neuralgia, • all painful and inflammatory Syndromes of Comprehensive Therapy.

The preparation has also proved successful in vertebrogenic difficulties.

The formulation replaces, for example, Ketazone 10% ung., Ketazonco-mlp. ung., Ung. Burr-owi and the like.

In clinical practice, the formulation has been tested for a longer period of time with a very good therapeutic effect. Tests were conducted at surgical-ambulance, surgical ward, and reu-matio-ambulance. The Bo-1 introduced the test into the practice of avionics and racing lures. Its use is particularly advantageous in the fields of rheumatoid, surgical, neurological, orthopedic, traumatic, and general medicine. In the widespread verification of the effect in 1000 surgical departments and surgical outpatient departments, the following treatment effect was achieved: excellent in 97.7%, good in 2.0%, without the e-fect u-0.3 ° / O.

During the trial, we did not eliminate any undesirable effects. In the skin isolation test, z10 patients in one experienced redness at the site of application. The preparation was tested in the regional test-drug where the p-odfa test of CSL was transferred. 3., which empowers us to prepare a healing product. On a worldwide scale, there are very frequent injuries and / or illnesses of the moving alparate, the treatment being considerably lengthy, patients complaining of pain at the site of the injury and the treatment often requires plaster, in the immobilization, what makes them temporarily out of normal life. Also, treatment is

Claims (2)

251545 5 do not differ in different workplaces and at the same time the cost of treatment is grilled. Pretobol is a hungry product that removes similar deficiencies. E.g. in only one surgical clinic, approximately 7,500 patients are treated each year with bruising of the musculoskeletal system and the musculoskeletal system. Often, long-term treatment with gypsum immobilization in some cases also requires constitutional treatment, while their weight cures for long-lived -bu. In the monitored group of patients with non-surgical illness, the time of burning was shortened during the use of the product and 4 to 7 days in the average. The treatment does not require tumor immobilization, which greatly improves patient mobility. Examples of Conversion a: Example 1 Mixing Benzocain 8 to 12 parts by weight, Ketophenylhutazones 8 to 12 parts by weight, 74 to 41 parts by weight of the ointment base resulted in pain relief in patients with inflammation of the superficial venous system of the saliva in 20 minutes after application of the composition and time the treatment lasted 4 days, with the condition of the patient requiring constitutional treatment at that time versus 10 to 14 days of the classical treatment. We prefer to reduce the pain in 20 minutes, reduce the tension and swelling of the damaged limb. Since immediate cooling effect is required in some diseases, Benzocaini 8 to 12 wt. Idielov, Ketophenylhutazon 8-112 wt. parts, ointment base 74 to 41 parts by weight, Aether 10 to 15 parts by weight; parts. Example 2 Patient Examined on Surgical Ambulance! with a diagnosis of sprain arthroplasty. After application of the above-mentioned ointment, the woman appeared in 30 minutes and the patient's condition required the wearing of an elastic charge for 7 days. In contrast to the Iclassic treatment, it required gypsum immobilization, and the dustiness of the patient, despite being a handyman. Physico-chemical properties of the product: Ointment, white, smooth, soft, cools and absorbs when applied to the skin. You can smell the ointment with ether. It requires storage in the refrigerator at + 5 ° C. From the past experience, the need to store the ointment on a dark place results in the above-mentioned heat. While maintaining the above, the active substance content, in relation to the properties of the preparation, is not changed for 5 months, which has been practically verified. Requirements for the size of the crystals suspended in the ointment are unambiguously determined by the addition of CsL 3, 1976. 80% of the suspended particles have a size of up to 40 µm and 20% to 60 (µm.). 'and CsL 3 general parts (p. 46 j. The results of previous tests entitle the pharmacist to prepare a satisfactory medical preparation while complying with the requirements of Csl 3 and Dopl.CsL 3, 1976. What is claimed is: 1. A medicament for the treatment of inflammatory and painful diseases which comprises 8 to 12 wt. parts, ketophenylbutazone in an amount of 8 to 12 wt. %, a pharmacologically / acceptable ointment base of 41 to 74% by weight. parts. 2. A medicament as claimed in claim 1, wherein the composition comprises an amount of ether in an amount of from 10 to 15% by weight. parts.